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Table
Characteristic N[67 (%)
Male 49 (73)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S80Patients who undergo AlloHCT with isolated CNS relapse
have superior outcome compared to those with combined
CNS and BM relapse or CNS involvement at diagnosis.Female 18 (27)
Age at Transplant
</30 31 (46)
>30 36 (54)
WBC at Diagnosis (x109/L)
<100 40 (60)
>100 8 (12)
Unknown 19 (28)
Extramedullary Disease at Dx
Yes 37 (55)
No 31 (45)
CNS Disease
Yes 8 (17)
No 5 (87)
Unk 1 (6)
Cytogenetics (SWOG)
Intermediate 37 (55)
High 2 (3)
Very High 4 (6)
BCR-ABL 2 (3)
Unknown 22 (33)
Disease Status at Transplant
CR1 21 (31)
CR2+ 31 (46)
NR/PD 15 (22)
Donor Source
Unrelated 29 (43)
Sibling 35 (52)
Parent 3 (5)
Stem Cell Source
BM 18 (27)
PBSC 42 (63)
CB 7 (10)
TBI 22 (33)
No TBI 45 (67)
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Introduction: T-ALL represents 20-25% of all cases of ALL,
with cure rates of 40% with chemotherapy alone. Allo-SCT
can improve survival in ﬁrst remission (CR1), and is the only
curative therapy for patients with relapsed or refractory
disease. We performed a review of all cases of T-ALL treated
with Allo-SCT at MDACC with the aim of identifying prog-
nostic markers to improve outcomes.
Methods: All patients who received ﬁrst allo-SCT for T-ALL
between 2000-2014were analyzed. Overall survival (OS) and
progression free survival (PFS) were estimated using the
Kaplan-Meier method. Cumulative incidence (CI) of relapse
(CIR), acute GVHD (aGVHD), and chronic GVHD (cGVHD)
were determined utilizing the cumulative incidence method
to account for competing risks. Given that disease relapse
was the primary cause of treatment failure, we evaluated
prognostic factors for relapse using Cox Proportional Haz-
ards regression analysis on univariate and multivariate
analysis.
Results: 67 patients received ﬁrst allo-SCT, with a median
age of 31 years (range 2-70), and a median follow-up time
among survivors of 35 months. 93% of patients received
myeloablative (MA) conditioning, with primarilytacroli-
mus/methotrexate +/- ATG GVHD prophylaxis (Table) The
3-year OS estimate was 34%, and 3-year PFS was 32%. In
patients transplanted in CR1, the OS was 57%, in CR2+,
30%, and in no-response/progressive disease (NR/PD) was
13%. The 3-year CIR was 54%, CI NRM 10% and CI cGVHD
23%. 100-day CIR II-IV aGVHD was 42%. On multivariate
analysis, male sex (HR 2.4, p¼0.055), and PD/NR (HR 2.9,
p¼0.003) were the only signiﬁcant predictors of relapse.
Minimal residual disease (MRD) by ﬂow cytometry at
transplant was predictive for relapse (HR 2.5, p¼0.03) on
univariate, but could not be analyzed on multivariate
analysis due to low numbers (n¼10), though 8/10 patients
died of relapse. CR1 vs CR2 on univariate was borderline
signiﬁcant (HR 3.96, p¼0.06). T-Cell subtyping will be
available at the time of presentation.
Conclusion:We present the largest single institutional study
of patients with T-ALL to date. Relapsewas themajor cause of
death in this cohort, with male sex and resistance to
chemotherapy as independent predictors of progression,
while transplant in CR1 trended to be advantageous for OS.
Novel strategies to decreaseMRD and relapse post transplant
are needed to improve outcomes.73
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